Startup aims for tailwind after Alzheimer's study involving Novo drug

Danish firm Kariya Pharma approaches phase I with a drug for Alzheimer's disease that exploits some of the same mechanisms as Novo's GLP-1 drugs. The company now plans to generate interest for the project following a major Alzheimer's conference with GLP-1 in the spotlight.

Kariya Pharmaceuticals CEO Ian Laquian | Photo: Kariya Pharmaceuticals PR

This year's Alzheimer's conference, CTAD, has been particularly exhilarating to Kariya Pharma's Chief Science Officer Christian Hölscher.

The conference included a milestone within one of the areas he has been most occupied with, that is, the effect of GLP-1 analogs on Alzheimer's disease. Specifically, it provided some results coming from the so-called ELAD study, which tested Novo Nordisk's analog liraglutide as a treatment for Alzheimer's.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs